Addressing the global disparity in cancer care necessitates the development of rapid and affordable nucleic acid (NA) testing technologies. This need is particularly critical for cervical cancer, where molecular detection of human papillomavirus (HPV) has emerged as an accurate screening method. However, implementing this transition in low- and middle-income countries has been challenging due to the high costs and centralized facilities required for current NA tests. Here, we present CreDiT (CRISPR Enhanced Digital Testing) for on-site NA detection. The CreDiT platform integrates i) a one-pot CRISPR strategy that simultaneously amplifies both target NAs and analytical signals and ii) a robust fluorescent detection based on digital communication (encoding/decoding) technology. These features enable a rapid assay (<35 minutes) in a single streamlined workflow. We demonstrate the sensitive detection of cell-derived HPV DNA targets down to single copies and accurate identification of HPV types in clinical cervical brushing specimens (n = 121).

解决全球癌症护理方面的差异需要开发快速且经济实惠的核酸 (NA) 检测技术。这种需求对于宫颈癌尤其重要，人乳头瘤病毒 (HPV) 的分子检测已成为一种准确的筛查方法。然而，由于当前 NA 测试所需的高成本和集中设施，在低收入和中等收入国家实施这种转变一直具有挑战性。在这里，我们推出了用于现场 NA 检测的 CreDiT（CRISPR 增强数字测试）。 CreDiT 平台集成了 i) 一锅 CRISPR 策略，可同时放大目标 NA 和分析信号，以及 ii) 基于数字通信（编码/解码）技术的强大荧光检测。这些功能可实现快速测定 (<35 id=72>n = 121)。